These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26450371)

  • 1. Emerging targets for combination therapy in melanomas.
    Saito Rde F; Tortelli TC; Jacomassi MD; Otake AH; Chammas R
    FEBS Lett; 2015 Nov; 589(22):3438-48. PubMed ID: 26450371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
    Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
    Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of combination treatment with checkpoint inhibitors in melanoma.
    Sullivan RJ
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
    [No Abstract]   [Full Text] [Related]  

  • 5. Marker utility for combination therapy.
    Simeone E; Grimaldi AM; Ascierto PA
    Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutics, chemoresistance and the management of melanoma.
    Rass K; Hassel JC
    G Ital Dermatol Venereol; 2009 Feb; 144(1):61-78. PubMed ID: 19218912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
    Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
    Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma: from darkness to promise.
    Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
    Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of systemic therapy of melanoma: combinations, predictive biomarkers.
    Tarhini AA
    Oncology (Williston Park); 2015 Feb; 29(2):94, 107. PubMed ID: 25683827
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting MAPK pathway in melanoma therapy.
    Cheng Y; Zhang G; Li G
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
    Mangiameli DP; Blansfield JA; Kachala S; Lorang D; Schafer PH; Muller GW; Stirling DI; Libutti SK
    J Transl Med; 2007 Jul; 5():38. PubMed ID: 17640369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma.
    Soares AS; Costa VM; Diniz C; Fresco P
    Biomed Pharmacother; 2013 Oct; 67(8):777-89. PubMed ID: 24035253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.